Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
Provided By GlobeNewswire
Last update: Feb 10, 2025
Data presented at the 2025 Crohn’s and Colitis Congress
PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure
Read more at globenewswire.comNASDAQ:PALI (8/27/2025, 2:02:04 PM)
0.6795
0 (-0.07%)
Find more stocks in the Stock Screener
PALI Latest News and Analysis
